The study from France seems to suck, though. Not very valuable data.

They measured virus, not outcomes, they measured virus in the throat, not the lungs, the starting point was not the start of the disease but some later (more arbitrary) point in time, the two groups were not randomly assigned and the study wasn’t really blind.

It could be that they just happened to compare two groups where the treatment group was further along in the illness – especially since they try to sell that as a disadvantage for them, but that could honestly be an advantage for them. We know that virus in the throat decreases as the illness progresses. (Virus in the lungs is much more relevant and also dangerous here, better would probably be outcomes.)

Not really evidence, sorry.